Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine vs docetaxel in metastatic non-squamous NSCLC (CEACAM5+)
CTR20200448Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Apr 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tusamitamab ravtansine in non-squamous non-small cell lung cancer, sponsored by Sanofi. Started Apr 2020; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on CTR20200448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200448.